Scarica l'app Stockscreener
5.58
3.46%
-0.20
Dopo l'orario di chiusura:
5.62
0.04
+0.72%
Precedente Chiudi:
$5.78
Aprire:
$5.7
Volume 24 ore:
72,014
Relative Volume:
5.33
Capitalizzazione di mercato:
$200.54M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.55
$5.7459
Intervallo di 1 settimana:
$5.40
$5.90
Portata 52W:
$5.40
$5.90
Anteris Technologies Global Corp Stock (AVR) Company Profile
Nome
Anteris Technologies Global Corp
Settore
Industria
Telefono
-
Indirizzo
-
Confronta AVR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
5.58 | 200.54M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Anteris Technologies Global Corp Borsa (AVR) Ultime notizie
Anteris Technologies’ Bold Shift to U.S. Markets - MSN
Admedus Limited to Relocate Corporate Services Functions to Brisbane; Announces Executive Changes - Marketscreener.com
Admedus Ltd : Admedus's CardioCel® Cleared for Sale in the US - Marketscreener.com
Anteris Technologies Redeems Convertible Notes - TipRanks
Anteris Technologies Announces New Director Appointment - TipRanks
Anteris Technologies Debuts on NASDAQ with IPO - MSN
Anteris Technologies Prepares for Stock Market Expansion - MSN
Anteris Completes Key Animal Study for EFS Submission - Marketscreener.com
Allied Healthcare Group Ltd : Allied reports no calcification from phase II CardioCel patients after 5 years - Marketscreener.com
Anteris Technologies Ltd Provides Data Update on First in Human Study of DurAVR THV Presented At New York Valves 2024 - Marketscreener.com
Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston - Marketscreener.com
Admedus Limited Appoints Maja Mcguire as Company Secretary - Marketscreener.com
Anteris Submits Confidential Draft Registration Statement for Proposed US IPO - Marketscreener.com
Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial - Marketscreener.com
Admedus Limited Announces Management Changes - Marketscreener.com
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering - Marketscreener.com
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study - Marketscreener.com
Anteris Technologies CEO talks A$35 million raise and 2023 milestones - Marketscreener.com
Anteris Technologies closes USD 88.8M US IPO - Medical Buyer
Anteris Technologies Completes $89 Million US IPO; to list CDIs on ASX; Shares Fall 15% - Marketscreener.com
Anteris Technologies Advances with SEC Filing - TipRanks
Anteris Technologies Completes $88.8M NASDAQ IPO for Revolutionary Heart Valve Development - StockTitan
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire
AVRAnteris Technologies Global Corp. Latest Stock News & Market Updates - StockTitan
Anteris Technologies Expands with U.S. IPO and Innovations - TipRanks
Anteris re-domiciliation finalised: shares trading on ASX and Nasdaq - Proactive Investors UK
Anteris Technologies goes public in U.S. - Minneapolis / St. Paul Business Journal
New Nasdaq Debut! - Jomfruland.net
Anteris Technologies Updates Bylaws to Enhance Governance - TipRanks
Anteris Technologies’ Strategic Move to the US - TipRanks
Anteris Technologies Launches New Equity Incentive Plan - TipRanks
Anteris Technologies Lists on Nasdaq Following IPO - TipRanks
Anteris Technologies lists on Nasdaq with IPO set at US$6.00 per share - Proactive Investors USA
Australian medtech Anteris stock slides 8% after $89M IPO - MSN
BTC Speciality Health Pty Ltd agreed to acquire Hospital Infusion Business from Admedus Limited. - Marketscreener.com
Admedus Limited announced that it has received AUD 6 million in funding - Marketscreener.com
U.S. IPO Weekly Recap: ServiceTitan Shines In 3 IPO Week - Seeking Alpha
Anteris Technologies Launches U.S. IPO on Nasdaq - TipRanks
Admedus : announces Placement and Rights Issue - Marketscreener.com
Anteris Technologies Ltd announced that it expects to receive funding from Mercer Street Capital Partners, LLC - Marketscreener.com
Anteris Technologies prices IPO at $6 per share (Pending:AVR) - Seeking Alpha
Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering - Yahoo Finance
Anteris Technologies Prices $88.8M Nasdaq IPO for Revolutionary Heart Valve Development - StockTitan
Allied Healthcare Group Ltd. Announces Board Changes - Marketscreener.com
Anteris Technologies Ltd Announces Fda Approves Early Feasibility Study for DurAVR THV System - Marketscreener.com
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4% - Marketscreener.com
Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study - Marketscreener.com
Anteris Technologies Announces Research Partnership with Yale University and Ycrg - Marketscreener.com
Anteris Technologies Ltd Overnight Presents 30-Day Clinical Data for Full Cohort of 13 Patients Implanted with DurAVR THV During Its First-In-Human Trial - Marketscreener.com
Anteris Technologies Ltd Presents "DurAVR transcatheter aortic valve first-in- human study: impact of novel leaflet design" at the annual PCR London Valves 2022, 27-29 November 2022 - Marketscreener.com
Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human) - Marketscreener.com
Anteris Technologies Global Corp Azioni (AVR) Dati Finanziari
Non sono disponibili dati finanziari per Anteris Technologies Global Corp (AVR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):